Mitochondrial Basis for Immune Deficiency: Evidence from Purine Nucleoside Phosphorylase-deficient Mice

By Enrico Arpaia, Patricia Benveniste, Antonio Di Cristofano, Yiping Gu, Ilan Dalal, Susan Kelly, Michael Hershfield, Pier Paolo Pandolfi, Chaim M. Roifman, and Amos Cohen

Abstract

We generated purine nucleoside phosphorylase (PNP)-deficient mice to gain insight into the mechanism of immune deficiency disease associated with PNP deficiency in humans. Similar to the human disease, PNP deficiency in mice causes an immunodeficiency that affects T lymphocytes more severely than B lymphocytes. PNP knockout mice exhibit impaired thymocyte differentiation, reduced mitogenic and allogeneic responses, and decreased numbers of maturing thymocytes and peripheral T cells. T lymphocytes of PNP-deficient mice exhibit increased apoptosis in vivo and higher sensitivity to gamma irradiation in vitro. We propose that the immune deficiency in PNP deficiency is a result of inhibition of mitochondrial DNA repair due to the accumulation of dGTP in the mitochondria. The end result is increased sensitivity of T cells to spontaneous mitochondrial DNA damage, leading to T cell depletion by apoptosis.

Key words: immune deficiency • apoptosis • mitochondria • purine metabolism • T lymphocyte

Introduction

An inherited deficiency in either one of the two purine salvage enzymes adenosine deaminase (ADA) or purine nucleoside phosphorylase (PNP) causes SCID disease (1, 2). Studies with mouse lymphoma T cell lines suggested that the impaired degradation of deoxyribonucleoside substrates of ADA and PNP leads respectively to accumulation of dATP or dGTP, which can inhibit ribonucleotide reductase activity, abrogating DNA synthesis or DNA repair (Fig. 1; references 3–6). dATP, but not dGTP, has also been found to form a complex with apoptotic protease-activating factor 1 (Apaf-1) and cytochrome C in the cytoplasm to activate caspases and induce apoptosis (7). Other mechanisms may also contribute to immunodeficiency associated with ADA deficiency, the more actively studied of the two disorders (8). However, the basis for immunodeficiency in PNP deficiency is still uncertain. Mice with PNP deficiency due to missense mutations showed a decline with age in numbers of immature and peripheral T cells and reduced T cell proliferation. In addition, mutations in PNP caused a secondary loss of deoxyguanosine kinase activity. The mechanism of the partial immune deficiency in these mice was not addressed.

To better address the mechanism of immunodeficiency, we generated totally PNP-deficient mice by homologous recombination. At an early age, PNP knockout mice exhibit T cell lymphopenia and abnormalities in T cell function. We propose that the abnormalities are due to selective accumulation of dGTP in the mitochondria of T cells,
A schematic presentation of the role of PNP in the degradation and salvage pathways of purine nucleosides is depicted. PNP catalyzes the phosphorolysis of the products of the ADA reaction, inosine and deoxyinosine, to yield hypoxanthine and ribose-1-phosphate. Deficiency in PNP enzymatic activity leads to the accumulation of its substrates, inosine, deoxyinosine, guanosine, and deoxyguanosine. Of the four PNP substrates, only deoxyguanosine is phosphorylated by the mitochondrial deoxyguanosine kinase (dGK). Further phosphorylation of dGMP leads to the accumulation of dGTP, which may interfere with DNA synthesis or repair directly or by inhibition of ribonucleotide reductase activity. The PNP product guanine is salvaged back to the guanine nucleotide pools by hypoxanthine guanine phosphoribosyl transferase (HGPR T) activity.

Materials and Methods

Generation of PNP<sup>−/−</sup> M mutant Mice. Murine cDNA for PNP was used for screening a genomic library of 129/Cj in λ-DASH phage vectors. Genomic clones were mapped and partially sequenced. A 7.0-kb genomic fragment containing the PNP catalytic sites within exons 3 and 4 was used to construct the targeting vector. A 1.2-kb genomic HindIII fragment containing exons 3 and 4 was replaced with a PGK neo-polA G418 resistance gene cassette (10) and a thymidine kinase (PGK-TK) expression cassette (11). E129/Cj embryonic stem cells (5×10<sup>9</sup>) were electroporated with 20 µg of linearized targeting vector DNA. The embryonic stem cells were cultured onto G418-resistant murine fibroblasts and selection, in the presence of 300 µg/ml G418 and 2 µM Ganclovir, was initiated 48 h after electroporation. Double-resistant colonies were isolated after 10 d. PCR screening for homologous recombination was carried out using the diagnostic primers spanning the PGK neo and the short arm of the construct (see Fig. 2 A). Homologous recombination was subsequently confirmed by EcoRI digestion of genomic DNA and hybridization with probe A (see Fig. 2). Chimeric mice were produced by injection of embryonic cells into 3.5-d-old blastocysts (10). The contribution of embryonic stem cells to the germline of chimeric mice was ascertained by breeding with 129/Cj mice. In vivo chimera production was confirmed by Southern blot analysis of tail DNA. Mice heterozygous for the mutant gene were interbred to homozygosity.

Enzyme Assays. PNP enzymatic activity was assayed in cell lysates using cellulose TLC with [8-<sup>14</sup>C]inosine (50 µCi/ml; Moravek Biochemicals, Inc.) as substrate, as described previously (3).

Deoxyguanosine kinase activity was assayed with [8-<sup>14</sup>H]2'-deoxyguanosine (4 µCi/ml; Moravek Biochemicals, Inc.) as described (12).

Analysis of Intracellular Nucleosides, GDP, and dGTP Pools. Intracellular nucleotides were extracted with 0.4 M ice-cold perchloric acid as described previously (13). After 5 min on ice, the cell extract was neutralized with 0.5 M tri-n-octylamine dissolved in 1,1,2-trichlorotrifluoroethane in the presence of 0.1% bro-mophenol blue until the solution changed to blue. Samples were centrifuged at 15,000 g for 1 min and frozen at −70°C until analyzed (14). Mitochondria were isolated by differential centrifugation (15). Nucleotides were separated on a Hewlett-Packard model 10848 chromatograph using a Partisil-5 SAX column (W. Hatman, Inc.; reference 3). Urinary nucleosides and deoxynucleosides were analyzed by reverse phase HPLC as described previously (3). Intracellular dGTP analysis was performed by the DNA polymerase method described by Sherman and Fyfe (16). Urinary nucleosides were determined using a C-18 reverse phase HPLC column (17).

Flow Cytometric Analysis. Flow cytometry was performed using a dual laser FACSscan<sup>™</sup> (Becton Dickinson). Single cell suspensions (10<sup>6</sup> cells) of either thymi, spleen, lymph node, or bone marrow were stained for three-color fluorescence analysis. Fluorescein-conjugated antibodies included CD3, TCR, IgM, and CD45 or CD34. Phycoerythrin-conjugated antibodies included CD4, CD11b, CD14, CD43, and Sca-1. Biotin-conjugated antibodies included CD8, IgM, NK1.1, CD19, B220, CD25, and CD24, and were developed with CyChrome streptavidin. All antibodies were purchased from BD Pharmingen. Control antibodies were FITC-Leu-4, PE-Leu-4, and biotin-Leu-1 (Becton Dickinson).

Anti-Fc receptor (CD16) antibody was used in all populations except thymus. Cells were washed in phosphate buffer containing 0.1% bovine albumin with 0.01% sodium azide (staining buffer) at 4°C. Pellets were then stained with the FITC-conjugated antibody at 4°C for 15 min, after which PE-conjugated antibody was added, and cells were further incubated for 30 min at 4°C. After washing twice in staining buffer, cells were stained with biotin-conjugated antibodies and incubated for 20 min at 4°C. CyChrome-streptavidin was added after washing, and after a further incubation of 15 min, cells were washed and resuspended in 0.5 ml of staining buffer, and were analyzed after filtering through a 0.8-µm filter and the addition of propidium iodide.

All fluorescence data were collected using logarithmic amplification on 10–50 K viable cells as determined by forward/side scatter and propidium iodide exclusion.

Determinations of Apoptosis. Annexin V binding was performed according to the manufacturer's instructions (Boehringer). In some experiments, as indicated, thymocytes were stained as described above with a combination of PE- and biotin-CyChrome-conjugated antibodies before annexin V staining. Previous experiments showed that the antibodies did not interfere with the annexin V stain. The PNP inhibitor, CI-1000 (2-aminopyridine-4H-pyrrole[3,2-d]-pyrimidine-4-one HCl), used in the apoptosis experiments were a gift of Dr. R.B. Gilbertsen (Parke-Davis). Mice overexpressing Bcl2 in thymocytes (described by Sentman et al. [18]) were obtained from the Jackson Laboratory.

Disipation of mitochondrial membrane potential (ΔΨ<sub>M</sub>) was determined using potentiometric sensitive fluorochrome, 3,3′ dihexyloxyacarbocyanine iodide (DiOC<sub>6</sub>; 20 nM) (19). Caspase activity was inhibited by N-benzyloxycarbonyl-Val-Ala-Asp fluoromethylketone (Z-Val-Asp-Ome; 50 µM).

Apoptotic nuclear DNA fragmentation was measured by the terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL) technique using an FITC-conju-
gated dUTP kit (Boehringer) according to the manufacturer's instructions. The frequency of apoptotic cells as detected by fragmented nuclear DNA was determined by flow cytometry. Cell isolations and cultures. Thymocytes were cultured for the amounts of time indicated, ranging from 2-12 h in complete medium (RPMI 1640 with 10% FCS, 0.1 M glutamine, and 0.05 M Hepes with 2 x 10^-5 M 2-ME) at 5 x 10^6 cells/ml in 24-well plates (Costar). In some experiments, TCR was cross-linked using purified anti-TCR mAb (20 µg/ml) and anti-CD3 mAb (145-2C11 mAb; 20 µg/ml), anti-CD4 mAb 1:4 vol of supernatant (R L172 [20]), and anti-CD8 mAb supernatant (3-155 [20]) for the time of culture. Cells were then washed and tested for apoptosis using the annexin V staining. Evidence for cross-linking was performed in these cultured cells by staining for the antigen being cross-linked with a specific mAb directed to this antigen.

Purified T cells derived from both lymph nodes and spleen of PNP-deficient as well as control mice were obtained by nylon wool depleting these populations. In brief, 5 x 10^7 cells nylon wool-packaged (Robbins Scientific) were poured into 10- or 20-ml syringes. Columns were preincubated for 45 min with the syringe volume of 1% BSA-PBS, and cells were loaded in 1-3 ml and incubated for another 45 min. Cells were then eluted with two column volumes, washed, and stained for CD3, CD11, and/or IgM mAb. Nylon wool lymph node T cells were on average >90% pure (range 86-98% in n = 16 experiments).

Cytotoxic T Cell Assay. Purified T cells derived from the spleens of PNP-deficient (H-2d) or wild-type controls were co-cultured with 20 C57BL/6 gamma-irradiated splenocytes derived from either CBA (H-2k) or DBA/2 (H-2d) at 10 x 10^6 responder with 10 x 10^6 irradiated stimulators in 20 ml final volume in flasks. Half of the cultures were supplemented with a previously tested optimal dose of rIL-2 (provided by Dr. R. Miller, University of Toronto, Toronto, Ontario). After 5 d, recovered cells were counted and used in a 4-h chromium assay at E/T ratios ranging from 2-100:1 in u-shaped 96-well plates. Each culture was assayed by the haplotype of the stimulator used, third party stimulator or syngeneic H-2k. The tumor cell lines (3,000 cells per well) P815 (H-2k) and BW5467 (H-2d) were used as targets.

Percentage cytotoxicity was calculated as (experimental release – spontaneous release) / (total release – spontaneous release) x 100. Spontaneous releases were <12%.

Gamma irradiation and T Lymphocyte Proliferation Assay. For gamma irradiation experiments T cells from the thymus or spleen were suspended in RPMI 1640 with 10% FCS at 10 x 10^6 cells/ml and were exposed to varying doses of gamma irradiation from a 137Cs irradiator. Total spleen or lymph node cells (3 x 10^6 cells) or nylon wool-purified T cells (3 x 10^6 cells) were cultured in complete medium in 96 flat-bottomed plates (Costar) in the presence of Con A (2 µg/ml) and IL-2 (10 U/ml). Lymphocyte proliferation was determined using [3H]thymidine added 4 h before the termination of the cultures.

Results

Generation of PNP-deficient Mice. We used homologous recombination to generate a mouse line that lacks PNP activity by replacing a 1.2-kb PNP gene fragment containing the catalytic site (nucleotides 324-870 spanning exons 3 and 4) with a neomycin (PGKneo) gene cassette (reference 11; Fig. 2). The selected PNP-deficient stem cell clones were injected into blastocysts of C57BL/6 mice to generate 129/C57BL/6 chimeric mice. After germline transmission of the targeted DNA, PNP-/- homozygosity was diagnosed using PCR of tail DNA and PNP enzyme assays (<0.2% of PN P<sup>+</sup>/+).

Metabolic abnormalities in PNP-deficient mice. To understand the metabolic consequences of PNP deficiency, we first analyzed the levels of PNP substrates excreted in their urine. The urine of PNP-deficient mice contains large amounts of the four PNP substrates (inosine, deoxyinosine, guanosine, and deoxyguanosine), similar to PNP-deficient patients (reference 17; Table IA). The intracellular concentration of GTP is reduced in PNP-/- cells, reflecting the lack of a guanosine kinase and inability to form (and hence salvage) guanine (Table IB; Fig. 1; reference 21, 22). In contrast, GTP pools were elevated by about eightfold in PNP-/- cells. As was proposed previously (14), phosphorylation of deoxyguanosine, the rate-limiting step in its conversion to dGTP, may be limited by an unexplained secondary loss of deoxyguanosine kinase activity found in cells of PNP-deficient mice (Table IB; Fig. 1; reference 23). In preliminary studies, we observed a substantial increase in whole blood PNP activity (20% of wild-type level) in each of three PNP knockout mice treated with polyethylene glycol (PEG)-modified PNP, which also eliminated the excretion of PNP substrates and alleviated the secondary loss of deoxyguanosine kinase activity (data not shown).

Because deoxyguanosine kinase localizes to the mitochondria (24-26), we have analyzed the distribution of in-
tracellular dGTP pools (Table I). We found a marked increase in dGTP associated with washed mitochondria from PNP-deficient thymocytes compared with mitochondria from PNP-expressing cells. Consistent with this observation, incubation of PNP-expressing thymocytes with deoxyguanosine in the presence of PNP inhibitor led to a large accumulation of dGTP in the mitochondria (data not shown). In contrast, incubation of thymocytes with the ADA inhibitor deoxycoformycin and deoxyadenosine resulted in a substantial increase of intracellular dATP pools, but no increase in mitochondrial dATP levels (data not shown). Thus, the localization of the respective deoxynucleoside kinases determines the intracellular location of dNTP pools because deoxycytidine kinase, the enzyme partially responsible for deoxyadenosine phosphorylation and with low affinity towards deoxyguanosine, is a nuclear enzyme (27).

Abnormalities in Lymphocyte Subpopulations in PNP-deficient Mice. Analysis of thymocyte subpopulations in PNP−/− mice reveals a twofold increase in the frequency of immature CD4−CD8− double negative (DN) cells and a decrease in the total cell numbers of CD4+CD8+ double positive (DP) and CD4+ and CD8+ single positive (SP) thymocytes (Fig. 3 A and Fig. 4 A). Similar to the thymus, both the spleen and lymph nodes of PNP-deficient mice exhibit increased numbers of CD4+ and CD8+ T cells (Fig. 3 A and Fig. 4 A). The spleen and lymph nodes of PNP-deficient mice also show an increase in the frequency of immature CD19+IgM+ pre-B cells with no concomitant change in the frequency of IgM+ mature B cells (Fig. 3 B and Fig. 4 B). The spleens of PNP−/− mice also contained increased numbers of CD11b+ myeloid cells (Fig. 4 B).

Table I. Urinary Levels of PNP Substrates, Intracellular Levels of Guanine Nucleotides, and Deyoxyguanosine Kinase Activity in Thymocytes from PNP-deficient Mice

| Mice   | Inosine | Guanosine | dInosine | dGuanosine |
|--------|---------|-----------|----------|------------|
| PNP−/− | 46.8 (9.7) | 34.5 (7.3) | 20.7 (2.7) | 16.5 (1.5) |
| PNP+/+ | <0.5   | <0.5      | <0.5     | <0.5       |

| Thymocytes | dGTP | GTP | Deoxyguanosine kinase | Mitochondrial dGTP |
|------------|------|-----|-----------------------|--------------------|
| PNP−/−     | 17.3 (2.8) | 695.7 (25.4) | 6.3 (0.9) | 0.45 (0.08) |
| PNP+/+     | 2.2 (0.74)  | 971.4 (32.8)  | 130.2 (9.8)  | <0.05    |

Nucleoside, deoxyribonucleoside, nucleotide, and deoxyguanosine levels and enzymatic activities were determined as described in Materials and Methods. Top: urinary nucleoside levels normalized to creatinine levels are averages of five individual daily measurements, with SD given in parentheses. Bottom: thymocyte dGTP, GTP, and deoxyguanosine levels represent averages of four individual mice, with SD given in parentheses.
Lymphocyte Function in PNP-deficient Mice. We assessed the function of T cells from PNP-deficient mice and tested the ability of cytotoxic T cells to specifically kill in a mixed lymphocyte reaction against H-2k- and H-2d-bearing stimulator cells. PNP-deficient spleen cells (H-2b) were cocultured for 5 d in the presence of irradiated spleen cells derived from either DBA/2 mice (H-2d; data not shown) or CBA mice (H-2k; Fig. 5). The cultures were set up in the presence or absence of IL-2. Recovered cells were then tested in a 4-h 51Cr-release assay for their ability to lyse allogeneic H-2k- targets or third party H-2b targets. In the absence of exogenous IL-2, H-2k-stimulated PNP-deficient T cells were unable to kill either H-2k-bearing or H-2d-bearing targets. However, in the presence of IL-2, the ability of PNP-deficient T cells to kill allogeneic H-2k cells was restored to a level comparable to that of their heterozygous littermates (Fig. 5). This observation suggests that T cells from PNP-deficient mice have an impaired ability to mount an immune response in the absence of exogenously added IL-2.

Enhanced Thymocyte Apoptosis in PNP Deficiency Is Initiated in the Mitochondria. To examine whether the depletion of DP thymocytes is due to enhanced apoptosis, we analyzed the frequency of apoptotic cells in thymocyte subpopulations from PNP-/- mice and their heterozygous littermates (Fig. 6). Freshly isolated PNP-deficient thymocytes show a twofold increase in the frequency of apoptotic thymocytes, measured by annexin V binding (28), compared with their heterozygous littermates. The frequency of apoptotic cells in the PNP-/- thymocyte subpopulation is inversely related to Bcl2 expression: it is highest at the DP stage (8.7% of total PNP-/- DP cells), lower in SP CD4 and CD8 cells, and absent in immature DN cells. To examine whether Bcl2 expression in the thymus may offer protection from apoptosis caused by PNP deficiency, we incubated thymocytes from C57BL/6 and Bcl2 transgenic mice (overexpressing Bcl2 in the thymus [18]) in the presence of deoxyguanosine and a PNP inhibitor (29). The frequency of apoptotic cells was monitored by annexin V binding. PNP inhibition in the presence of deoxyguanosine significantly (P < 0.05) reduced the frequency of apoptotic cells compared with controls (Fig. 7). These data suggest that PNP may play a role in the regulation of thymocyte apoptosis through a mechanism involving Bcl2 expression.
nosine caused increased thymocyte apoptosis in C57BL/6 (Fig. 7). Deoxyguanosine or PNP inhibitor added separately did not affect the frequency of apoptotic thymocytes. Overexpression of Bcl2 in thymocytes from transgenic mice completely protects against deoxyguanosine-induced apoptosis in the absence of PNP activity. No apoptosis was induced by any of the other three PNP substrates (inosine, deoxyinosine, or guanosine) in the presence of the PNP inhibitor (data not shown).

Dissipation of Δψm is an early apoptotic event that is independent of caspase activity for intramitochondrial apoptotic agents, but Δψm is dependent on caspase activity if the apoptotic signal is extramitochondrial (19). Thus, resistance of Δψm to caspase inhibition is indicative of apoptotic signals that originate within the mitochondria. Deoxyguanosine in the presence of PNP inhibitor caused rapid dissipation of Δψm similar to other apoptosis-inducing agents. This dissipation of Δψm was resistant to cytosolic caspase inhibition, indicating that deoxyguanosine initiates apoptosis within the mitochondria (Fig. 8). In contrast, the deoxyguanosine-induced fragmentation of nuclear DNA, a late event in apoptosis, was inhibited by caspase inhibitor. These results are consistent with the hypothesis that accumulation of dGTP in the mitochondria is responsible for the apoptosis observed in PNP-deficient thymocytes.

Sensitivity of PNP-deficient T Cells to Gamma Irradiation. Imbalance of dNTP pools has been shown to interfere with DNA repair (5, 30–32). We have examined the possibility that mitochondrial dGTP accumulation may predispose PNP-deficient T cells to DNA damage. Thymocytes from PNP-deficient mice exhibit increased sensitivity to gamma irradiation compared with their heterozygous littermates. After 12 h of incubation after gamma irradiation, 50% apoptosis was observed at about 200 cGy, whereas a dose of 1,000 cGy was needed to induce 50% apoptosis in thymocytes from heterozygous mice (Fig. 9).

To assess the sensitivity of peripheral T cells to gamma irradiation, splenocytes from PNP-deficient mice and their heterozygous littermates were gamma irradiated, and their proliferation was monitored after stimulation by Con A (Fig. 10). Exogenous IL-2 was added to all cultures, as PNP-deficient T cells have decreased mitogenic response.
in the absence of IL-2 (data not shown; references 9, 33). Similar to PNP-deficient thymocytes, mature T cells from the spleens of PNP-deficient mice are more sensitive to gamma irradiation (90% reduction at 300 cGy) than their heterozygous littermates (90% reduction at 800 cGy). These observations are consistent with an impaired DNA repair in PNP-deficient thymocytes.

Discussion

In humans, PNP gene mutations that result in extensive loss of enzymatic activity cause severe T cell deficiency with variable abnormalities in humoral immunity (2, 34–37). Similar to the human disease, PNP deficiency in mice causes an immunodeficiency that affects T lymphocytes more severely than B lymphocytes. PNP knockout mice exhibit impaired thymocyte differentiation (Fig. 3), reduced mitogenic and allogeneic responses (Fig. 5; data not shown), and decreased numbers of maturing thymocytes and peripheral T cells (Fig. 3 and Fig. 4 A). Mice with less complete PNP deficiency because of missense mutations showed a more gradual postnatal decline in T cell numbers and in T cell function (9, 33). PNP knockout mice provide a good experimental model for studying the biochemical basis of immunodeficiency, and for testing potential therapies for the disease in humans. Preliminary studies suggest that a previously developed PEG-PNP that shows reduced immunogenicity in normal mice (38) corrects the metabolic abnormalities and prolongs the life of PNP knockout mice.

The immune deficiency disease caused by loss of PNP enzymatic activity could be due to either interference with purine salvage resulting in depletion of GTP or to the ac-
cumulation of one or more of the PNP substrates inosine, guanosine, deoxyinosine, and deoxyguanosine. Decreased intracellular levels of GTP observed in PNP deficiency (Table I) are unlikely to contribute to the immune dysfunction, as a similar decrease in intracellular levels of GTP in hypoxanthine guanine phosphoribosyl transferase (HGPRT) deficiency has no effect on immune function in patients with Lesch-Nyan syndrome (39). The only other intracellular metabolic abnormality in PNP−/− mice, as well as in PNP+− mice, is the expansion of intracellular dGTP pools (Table I), which are normally tightly regulated in mammalian cells (40, 41).

The observed increase in intracellular dGTP pools in PNP deficiency is modest (17 pmol/10^6 cells, or eightfold normal levels) compared with the 4–5 mM concentration of deoxyguanosine accumulated in the urine of these mice (Table I). This may be partly explained by end product inhibition of deoxyguanosine kinase activity by dGTP (42, 43). In addition, cells from PNP−/− mice exhibit a secondary loss of deoxyguanosine kinase activity in all tissues examined, further limiting the potential of deoxyguanosine accumulation (Table I B; reference 14). The underlying mechanisms have not been established, although partial restoration of deoxyguanosine kinase activity after treatment with PEG-PNP clearly indicates an effect of a PNP substrate or metabolite. It is not clear whether deoxyguanosine kinase activity is reduced in cells of human patients with PNP deficiency. However, in PNP-deficient mice, this effect is likely to moderate the immune dysfunction, and perhaps prevents the neurologic abnormalities often present in human patients.

The observations described here, particularly the evidence that dGTP accumulation occurs selectively in mitochondria (Table I) and that PNP-deficient thymocytes and splenic T cells show increased sensitivity to irradiation (Table I; Fig. 10), offer new insight into the biochemical basis for immunodeficiency. We postulate that accumulation of dGTP in the mitochondria of T lymphocytes initiates apoptosis by interfering with the repair of mitochondrial DNA damage. This hypothesis is supported by several observations. The mitochondrial and T cell specificity of dGTP accumulation are consistent with the subcellular localization (44) and tissue distribution (13, 45, 46) of deoxyguanosine kinase activity. Human deoxyguanosine kinase activity is localized exclusively in the mitochondria, and thus dGTP accumulates as expected in the mitochondria (47). That dGTP accumulation preferentially inhibits mitochondrial DNA synthesis or repair rather than nuclear DNA synthesis is suggested by the finding that PNP-deficient cells are sensitive to gamma irradiation, but are able to replicate their nuclear DNA in response to mitogen in the presence of IL-2 (Fig. 10).

Other observations provide additional evidence that the T cell damage in PNP deficiency originates in the mitochondria. Overexpression of deoxyguanosine kinase in the mitochondria leads to increased sensitivity to anticancer deoxyguanosine analogues (48). dGTP-mediated inhibition of mitochondrial DNA synthesis or repair might also initiate apoptosis by inducing release of cytochrome C into the cytoplasm.

Recently, the mutations responsible for the human mitochondrial disease neurogastrointestinal encephalomyopathy (MNGIE) were localized to the thymidine phosphorylase (TP) gene. TP phosphorylates thymine to yield thymidine, and thus has parallel activity in the pyrimidine salvage pathway to that of PNP in the purine salvage pathway (49). Patients with MNGIE syndrome have multiple deletions in their mitochondrial DNA and develop a muscular neurological disorder starting in their twenties. It has been postulated that dTTP accumulation in the mitochondria of these patients may be responsible for abnormalities in mitochondrial DNA synthesis and repair (49). Although the tissue-specific phenotype in the two diseases may vary according to the specific tissue expression of the respective kinases, it is likely that the neurologic defects, including cerebral ataxia, common to PNP-deficient and MNGIE patients (35, 50–52) may similarly be due to inhibition of mitochondrial DNA maintenance by either dGTP or dTTP (Fig. 11).

![Figure 11. Proposed mechanism of PNP, ADA, and TP deficiencies.](image-url)
The T lymphocyte specificity of PNP deficiency may be due in part to the increased capability of T cells and thymocytes to accumulate purine dNTPs (13, 53, 54). On the other hand, stimulation of T cell thymocytes through their antigen receptor often leads to activation-induced apoptosis, a process that requires activation threshold to recruit the mitochondrial apoptotic apparatus (55, 56). It is thus possible that mitochondrial dGTP accumulation in PNP deficiency will lower that apoptotic threshold.

Mitochondrial DNA repair is of critical importance in view of the increased frequency of mitochondrial DNA damage compared with nuclear DNA (20-fold higher; reference 57). The immediate effects of deoxyguanosine-induced apoptosis suggest the existence of an early detection mechanism of accumulation of mitochondrial DNA damage leading to the activation of mitochondrial apoptosis. The mechanisms that link nuclear DNA damage to apoptosis are under intensive investigation and include the participation of p53, ataxia telangiectesia mutated gene (ATM), and possibly dATP (7, 58–60). In contrast, little is known about the mechanisms that link mitochondrial DNA damage to apoptosis. Changes in mitochondrial dNTP levels such as dGTP and dTTP may participate in linking mitochondrial DNA damage to apoptosis, analogous to the role of dATP in apoptosis and in nuclear DNA repair (7, 60). The PNP-deficient mice provide an excellent model to test this hypothesis further.

This work was partially supported by grants from the Medical Research Council of Canada and the Canadian Genetic Diseases Network to A. Cohen and C.M. Roifman. M.S. Hershfield’s contribution was supported by National Institutes of Health grant DK-20902. C.M. Roifman is the Donald & Audrey Campbell Chair of Immunology.

Submitted: 24 January 2000
R evised: 20 March 2000
A ccepted: 3 April 2000

References

1. Giblett, E.R., J.E. Anderson, F. Cohen, B. Pollara, and H.J. M euwissen. 1972. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet. 2:1067–1069.
2. Giblett, E.R., A.J. Ammann, D.W. W ara, R. Sandman, and L.K. Diamond. 1975. Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet. 1:1010–1013.
3. Cohen, A., L.J. Gudas, A.J. Ammann, G.E. Staal, and D.J. Martin. 1978. Deoxyguanosine triphosphate as a possible toxic metabolite in the immunodeficiency associated with purine nucleoside phosphorylase deficiency. J. Clin. Invest. 61:1405–1409.
4. Cohen, A., R. Hirschhorn, S.D. Horowitz, A. Rubinstein, S.H. Polmar, R. Hong, and D.J. Martin. 1978. Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc. Natl. Acad. Sci. USA. 75: 472–476.
5. Gudas, L.J., B. Ulman, A. Cohen, and D.J. Martin. 1978. Deoxyguanosine toxicity in a mouse T lymphoma relationship to purine nucleoside phosphorylase-associated immune dysfunction. Cell. 14:531–538.
6. Ulman, B., L.J. Gudas, A. Cohen, and D.J. Martin. 1978. Deoxyadenosine metabolism and cytotoxicity in cultured mouse T lymphoma cells: a model for immunodeficiency disease. Cell. 14:365–375.
7. Li, P., D. Nihawan, I. Budihardjo, S.M. Srinivasula, M. Ahmad, E.S. Alnemri, and X. Wang. 1997. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 91:479–489.
8. Hershfield, M.S., and B.S. Mitchell. 1995. Immunodeficiency diseases caused by adenosine deaminase and purine nucleoside deficiency. In T The Metabolic and Molecular Basis of Inherited Disease. C.R. Scriver, A.L. R eaudet, M.S. Sly, editors. McGraw-Hill Inc., New York. 1725–1768.
9. Snyder, F.F., J.P. Jenuth, E.R. M ably, and R.K. Mangat. 1997. Point mutations at the purine nucleoside phosphorylase locus impair thymocyte differentiation in the mouse. Proc. Natl. Acad. Sci. USA. 94:2522–2527.
10. Thomas, K.R., and M.R. C apecci. 1987. Site-directed mutagenesis by gene targeting in mouse embryonic stem cells. Cell. 51:503–512.
11. Tybulewicz, V.L., C.E. Crawford, P.K. Jackson, R.T. Bronson, and R.C. Mulligan. 1991. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell. 65:1153–1163.
12. Yamada, Y., H. Goto, and N. Ogawa. 1983. Purine nucleoside kinases in human T- and B-lymphoblasts. Biochim. Biophys. Acta. 761:34–40.
13. Cohen, A., J. Barankiewicz, H.M. L ederman, and E.W. Gel fand. 1983. Purine and pyrimidine metabolism in human T lymphocytes. Regulation of deoxyribonuclease metabolism. J. Biol. Chem. 258:12334–12340.
14. Snyder, F.F., J.P. Jenuth, J.E. Dilay, E. Fung, T. Lightfoot, and E.R. M ably. 1994. Secondary loss of deoxyguanosine kinase activity in purine nucleoside phosphorylase deficient mice. Biochim. Biophys. Acta. 1227:33–40.
15. Trounce, I.A., Y.L. Kim, A.S. Jun, and D.C. Wallace. 1996. Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines. Methods Enzymol. 264:484–509.
16. Sherman, P.A., and J.A. F yfe. 1989. Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers. Anal. Biochem. 180:222–226.
17. Cohen, A., D. Doyle, D.W. M artin, and A.J. Ammann, Jr. 1976. Abnormal purine metabolism and purine overproduction in a patient deficient in purine nucleoside phosphorylase. N. Engl. J. Med. 295:1449–1454.
18. Sentman, C.L., J.R. Shutter, D. Hockenbery, O. Kanagawa, and S.J. Korsmeyer. 1991. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell. 67: 879–888.
19. Ravagnan, L., I. Marzo, P. Costantini, S.A. Susin, N. Zammam, P.X. Petit, F. Hirsch, M. Goulbourn, M.F. Poupon, L. Miccoli, et al. 1999. Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore. Oncogene. 18:2537–2546.
20. West, D.L., L. Yuan, J. Jefferson, P. Benveniste, M. Tsokos, R.D. Klausner, L.H. Glimcher, L.E. Samelson, and A. Singer. 1993. Regulation of T cell receptor expression in immature CD4+CD8+ thymocytes by p56lck tyrosine kinase: basis for differential signaling by CD4 and CD8 in immature
thymocytes expressing both coreceptor molecules. J. Exp. Med. 178:1701–1712.

21. Simmonds, H.A., A.R. Watson, D.R. Webster, A. Sahota, and D. Perrett. 1982. GTP depletion and other erythrocyte abnormalities in inherited PNP deficiency. Biochem. Pharmacol. 31:941–946.

22. Cohen, A., J. Barankiewicz, H.M. Lederman, and E.W. Gelfand. 1984. Purine metabolism in human T lymphocytes: role of the purine nucleoside cycle. Can. J. Biochem. Cell Biol. 62:577–583.

23. Jenuth, J.P., J.E. Dilay, E. Fung, E.R. Mably, and F.F. Snyder. 1993. Absence of dGTP accumulation and compensatory loss of deoxyguanosine kinase in purine nucleoside phosphorylase deficient mice. Adv. Exp. Med. Biol. 309B:273–277.

24. Johansson, M., and A. Karlsson. 1996. Cloning and expression of human deoxyguanosine kinase cDNA. Proc. Natl. Acad. Sci. USA. 93:7258–7262.

25. Park, I., and D.H. Ives. 1988. Properties of a highly purified mitochondrial deoxyguanosine kinase. Arch. Biochem. Biophys. 266:51–60.

26. Zhu, C., M. Johansson, J. Perment, and A. Karlsson. 1998. Phosphorylation of anticancer nucleoside analogs by human mitochondrial deoxyguanosine kinase. Biochem. Pharmacol. 56:1035–1040.

27. Johansson, M., S. Brismar, and A. Karlsson. 1997. Human deoxyxycytidine kinase is located in the cell nucleus. Proc. Natl. Acad. Sci. USA. 94:11941–11945.

28. Ernst, J.D., L. Yang, J.L. Rosales, and V.C. Broadus. 1998. Preparation and characterization of an endogenously fluorescent annexin for detection of apoptotic cells. Anal. Biochem. 260:18–23.

29. Posmantur, R., K.K. Wang, R. Nath, and R.B. Gilbertsen. 1997. A human purine nucleoside phosphorylase (PNP) inhibitor induces apoptosis via caspase-3-like protease activity in MOLT-4 T cells. Immunopharmacology. 37:231–244.

30. Ul厦门市, B., L.J. Guda, S.M. Clift, and D.J. Martin. 1979. Isolation and characterization of purine-nucleoside phosphorylase-deficient T-lymphoma cells and secondary mutants with altered ribonucleotide reductase: genetic model for immunodeficiency disease. Proc. Natl. Acad. Sci. USA. 76:1074–1078.

31. Cohen, A., and E. Thompson. 1986. DNA repair in nondividing human lymphocytes inhibition by deoxyadenosine. Cancer Res. 46:1585–1588.

32. Martin, D.J., and E.W. Gelfand. 1981. Biochemistry of diseases of immunodevelopment. Annu. Rev. Biochem. 50:845–877.

33. Snyder, F.F., J.P. Jenuth, E.R. Mably, R.K. Mangat, and R.A. Pinto. 1998. Purine nucleoside phosphorylase deficient mice exhibit both an age dependent attrition of thymocytes and impaired thymocyte differentiation. Adv. Exp. Med. Biol. 431:515–518.

34. Sandman, R., A.J. Ammann, C. Grose, and D.W. Wara. 1977. Cellular immunodeficiency associated with nucleoside phosphorylase deficiency. Immunologic and biochemical studies. Clin. Immunol. Immunopathol. 8:247–253.

35. Stoop, J.W., B.J. Zegers, G.F. Hendrickx, H.L. van Haekelom, G.E. Staats, P.K. de Bree, S.K. Wadman, and R.E. Balilioux. 1977. Purine nucleoside phosphorylase deficiency associated with selective cellular immunodeficiency. N. Engl. J. Med. 296:651–655.

36. Markert, M.L. 1991. Purine nucleoside phosphorylase deficiency. Immunodef. Rev. 3:45–81.

37. Cohen, A., E. Grunbaum, E. Arpaia, and C.M. Rolfman. 2000. Immunodeficiency caused by purine nucleoside phosphorylase deficiency. In Clinics of North America. C.M. Rolfman, editor. W.B. Saunders Co., Philadelphia. 129–159.

38. Hershfield, M.S., S. Chaffee, J.L. Koro, A. Mary, A.A. Smith, and S.A. Short. 1991. Use of site-directed mutagenesis to enhance the epitone-shielding effect of covalent modification of proteins with polyethylene glycol. Proc. Natl. Acad. Sci. USA. 88:7185–7189.

39. Sidi, Y., I. Gelv, S. Brosh, J. Pinkhas, and O. Sperling. 1989. Guanine nucleotide metabolism in red blood cells: the metabolic basis for GTP depletion in HPRT and PNP deficiency. Adv. Exp. Med. Biol. 153B:67–71.

40. Bjursell, G., and L. Skoog. 1980. Control of nucleotide pools in mammalian cells. Anibiot. Chemother. 28:78–85.

41. Riechard, P. 1985. Ribonucleoside reductase and deoxyribonucleotide pools. Basic Life Sci. 31:33–45.

42. Park, I., and D.H. Ives. 1995. Kinetic mechanism and end-product regulation of deoxyguanosine kinase from beef liver mitochondria. J. Biochem. 117:1058–1061.

43. Yamada, Y., H. Goto, and N. Ogasawara. 1983. Regulation of human placental deoxyguanosine kinase by nucleotides. FEBS Lett. 157:51–53.

44. Wang, L., U. Hellman, and S. Eriksson. 1996. Cloning and expression of human mitochondrial deoxyguanosine kinase cDNA. FEBS Lett. 390:39–43.

45. Eriksson, S., E. Arner, T. Spakoukotstaka, L. Wang, A. Karlsson, O. Brojo, P. Gunven, G. Julusson, and J. Lillemark. 1994. Properties and levels of deoxynucleoside kinases in normal and tumor cells: implications for chemotherapy. Adv. Enzyme Regul. 34:13–25.

46. Carson, D.A., J. Kaye, and J.E. Seegmiller. 1977. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s). Proc. Natl. Acad. Sci. USA. 74:5677–5681.

47. Johansson, M., S. Bajalica-Lagercrantz, J. Lagercrantz, and A. Karlsson. 1996. Localization of the human deoxyguanosine kinase gene (GDUOK) to chromosome 2p13. Genomics. 38:450–451.

48. Zhu, C., M. Johansson, J. Perment, and A. Karlsson. 1998. Enhanced cytotoxicity of nucleoside analogs by overexpression of mitochondrial deoxyguanosine kinase in cancer cell lines. J. Biol. Chem. 273:14707–14711.

49. Nishino, I., A. Spinazzola, and M. Hirano. 1999. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science. 283:689–692.

50. Sakiyama, T. 1996. [Purine nucleoside phosphorylase (PNP) deficiency]. Nippon Rinsho. 54:3328–3332.

51. Simmonds, H.A., L.D. Fairbanks, G.S. Morris, G. Morgan, A.R. Watson, P. Timms, and B. Singh. 1987. Central nervous system dysfunction and erythrocyte guanosine triphosphate depletion in purine nucleoside phosphorylase deficiency. Arch. Dis. Child. 62:385–391.

52. Tam, D.J., and R.T. Lesher. 1995. Stroke in purine nucleoside phosphorylase deficiency. Pediatr. N. Engl. J. Med. 332:146–148.

53. Cohen, A., J.W. Lee, H.M. Dosch, and E.W. Gelfand. 1980. The expression of deoxyguanosine toxicity in T lymphocytes at different stages of maturation. J. Immunol. 125:1578–1582.

54. Carson, D.A., D.B. Wason, E. Lakow, and N. Kamitani. 1982. Possible metabolic bases for the different immunodeficient states associated with genetic deficiencies of adenosine phosphorylase-deficient Immune-deficient Mice.

2206 Purine Nucleoside Phosphorylase-deficient Immune-deficient Mice
deaminase and purine nucleoside phosphorylase. Proc. Natl Acad. Sci. USA. 79:3848–3852.
55. Hildeman, D.A., T. Mitchell, T.K. Teague, P. Henson, B.J. Day, J. Kappler, and P.C. Marrack. 1999. Reactive oxygen species regulate activation-induced T cell apoptosis. Immunity. 10:735–744.
56. Marchetti, P., T Hirsch, N. Zamzami, M. Castedo, D. Decaudin, S.A. Susin, B. Masse, and G. Kroemer. 1996. Mitochondrial permeability transition triggers lymphocyte apoptosis. J. Immunol. 157:4830–4836.
57. Croteau, D.L., and V.A. Bohr. 1997. Repair of oxidative damage to nuclear and mitochondrial DNA in mammalian cells. J. Biol. Chem. 272:25409–25412.
58. Canman, C.E., and D.S. Lim. 1998. The role of ATM in DNA damage responses and cancer. Oncogene. 17:3301–3308.
59. Karlseder, J., D. Broccoli, Y. Dai, S. Hardy, and T. de Lange. 1999. p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science. 283:1321–1325.
60. Benveniste, P., and A. Cohen. 1995. p53 expression is required for thymocyte apoptosis induced by adenosine deaminase deficiency. Proc. Natl Acad. Sci. USA. 92:8373–8377.
61. Wang, L., P.B. Munch, S.A. Herrstrom, U. Hellman, T. Bergman, H. Jornvall, and S. Eriksson. 1999. Human thymidine kinase 2: molecular cloning and characterisation of the enzyme activity with antiviral and cytostatic nucleoside substrates. FEBS Lett. 443:170–174.
62. Young, P., J.M. Leeds, M.B. Slabaugh, and C.K. Mathews. 1994. Ribonucleotide reductase: evidence for specific association with HeLa cell mitochondria. Biochem. Biophys. Res. Commun. 203:46–52.